✦ LIBER ✦

Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma

✍ Scribed by Keith T. Flaherty; Igor Puzanov

Book ID: 113489200
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 253 KB
Volume: 80
Category: Article
ISSN: 0006-2952
DOI: 10.1016/j.bcp.2010.04.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A systematic review of predictive and pr

A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma

✍ Funakoshi, Tomohiro; Lee, Chung-Han; Hsieh, James J. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 519 KB

Vascular endothelial growth factor and m

Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms

✍ Peter Mulders 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB

202 MTOR PATHWAY IN PAPILLARY RENAL CELL

202 MTOR PATHWAY IN PAPILLARY RENAL CELL CARCINOMA (PAPRCC): PROGNOSTIC ROLE AND POTENTIAL TARGET OF THERAPY

✍ Schultz, Luciana; Albadine, Roula; Hicks, Jessica; De Marzo, Angelo; Reuter, Vic 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 42 KB

Classification of renal cell carcinoma b

Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells

✍ Kluger, Harriet M; Siddiqui, Summar F; Angeletti, Cesar; Sznol, Mario; Kelly, Wi 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 607 KB

Combination of targeted agents in metast

Combination of targeted agents in metastatic renal cell carcinoma : A path forward or a dead-end street?

✍ M. Dror Michaelson 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 726 KB

Prognostic relevance of the mTOR pathway

Prognostic relevance of the mTOR pathway in renal cell carcinoma : Implications for molecular patient selection for targeted therapy

✍ Allan J. Pantuck; David B. Seligson; Tobias Klatte; Hong Yu; John T. Leppert; La 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 980 KB

## Abstract ## BACKGROUND. The mammalian target of rapamycin (mTOR) pathway is up‐regulated in many human cancers, and agents targeting the mTOR pathway are in various stages of clinical development. The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway